$AVR

L1 Capital Pty Ltd sold $4.3M of AVR (indirect holdings)

L1 Capital Pty Ltd sold 524,404 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at an average of $8.10 ($8.10–$8.15, $4.25M total) across 2 trades over 2026-07-31 to 2026-08-03.

Original reporting
SEC EDGAR · L1 Capital Pty Ltd
Published Aug 4, 2026, 10:23 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 4, 2026, 10:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AVR
Neutral
medium confidence
Mentioned
$AVR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVRNeutralLow
01

Why it matters

The newest information is the disclosed sale size, price range, and post-transaction share count, which can influence short-term sentiment but lacks fundamental drivers in the text.

02

Market read

A $4.25M open-market sale by a 10% owner is newly disclosed, offering a modest sentiment signal for AVR without new business or financial guidance.

03

What to watch

Indirect holdings and the absence of a stated 10b5-1 plan do not, by themselves, confirm bearish expectations; traders should watch for subsequent Form 4s and any concurrent company disclosures.

Relevance 6/10Novelty 5/10Timing: filed today, covering sales from 2026-07-31 to 2026-08-03

Background

This is an SEC Form 4 insider transaction disclosure for Anteris Technologies Global Corp. (AVR), reported by L1 Capital Pty Ltd as a 10% owner via indirect holdings.

Company-level read

Ticker impact

$AVRNeutralMedium confidence
Context

Anteris Technologies Global Corp. (AVR) disclosed an open-market sale by a 10% owner, L1 Capital, totaling about $4.25M at ~$8.10/share.

Expected impact

Likely limited, short-lived sentiment impact unless follow-on selling or additional filings emerge.

Evidence & confidence

Form 4 shows an indirect open-market sale with no 10b5-1 plan stated, but the article provides no new operational, financial, or regulatory catalyst for AVR.

Market effects

Minimal, as this is a single-company insider transaction with no sector-wide regulatory or competitive change.

None indicated.

None indicated.

Counterpoint

The sale could be liquidity-driven or portfolio rebalancing, especially since the filing does not cite any adverse company development.

Key entities

  • Anteris Technologies Global Corp.

    Subject of the Form 4 insider transaction disclosure, ticker AVR.

  • L1 Capital Pty Ltd

    Reporter of the indirect open-market sale totaling $4.25M across two trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AVRMedAI 8/10

Small Cap watch: ASX small caps ease after strong week as NewPeak, Orthocell and Anteris advance drilling, sales and data

The S&P/ASX Small Ordinaries Index fell 0.74% on Friday but gained 3.03% over the week. NewPeak Metals completed drilling in Argentina, Orthocell reported record US sales, and Anteris Technologies released positive heart valve data. NewPeak tested gold mineralization, Orthocell sold 92 units of Remplir, and Anteris' valve showed improved haemodynamics in 22 patients.

$AVRMedAI 8/10

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

Anteris Technologies (NASDAQ: AVR, ASX: AVR) reported 30-day outcomes for its DurAVR THV in 22 patients with medium aortic annuli, showing positive hemodynamic and safety results. The DurAVR THV is being evaluated in the ongoing PARADIGM trial, a global study comparing it to commercially available TAVRs. The company aims to confirm the valve's effectiveness in a randomized setting.

$AVRMedAI 8/10

Anteris Technologies secures German clearance to expand PARADIGM heart valve trial

Anteris Technologies (ASX:AVR, NASDAQ:AVR) received German regulatory approval to expand its PARADIGM heart valve trial, allowing patient recruitment in Europe's largest market. The trial aims to enroll 1,000 patients to evaluate the DurAVR valve against existing devices. The company expects Germany's expertise to accelerate enrollment. DurAVR is a transcatheter heart valve designed to mimic a healthy aortic valve.